Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.28 EUR
−147.74 M EUR
0.00 EUR
39.59 M
About ABIVAX
Sector
CEO
Marc M. P. de Garidel
Headquarters
Paris
Website
Founded
2013
ISIN
FR0012333284
FIGI
BBG00GNG2LJ4
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2X1 is 7.00 EUR — it hasn't changed in the past 24 hours. Watch ABIVAX SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ABIVAX SA stocks are traded under the ticker 2X1.
2X1 stock has risen by 3.86% compared to the previous week, the month change is a −10.83% fall, over the last year ABIVAX SA has showed a −28.06% decrease.
We've gathered analysts' opinions on ABIVAX SA future price: according to them, 2X1 price has a max estimate of 47.59 EUR and a min estimate of 18.00 EUR. Watch 2X1 chart and read a more detailed ABIVAX SA stock forecast: see what analysts think of ABIVAX SA and suggest that you do with its stocks.
2X1 stock is 5.64% volatile and has beta coefficient of 1.33. Track ABIVAX SA stock price on the chart and check out the list of the most volatile stocks — is ABIVAX SA there?
Today ABIVAX SA has the market capitalization of 448.42 M, it has decreased by −0.84% over the last week.
Yes, you can track ABIVAX SA financials in yearly and quarterly reports right on TradingView.
ABIVAX SA is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
2X1 earnings for the last half-year are −1.30 EUR per share, whereas the estimation was −1.37 EUR, resulting in a 5.34% surprise. The estimated earnings for the next half-year are −1.47 EUR per share. See more details about ABIVAX SA earnings.
ABIVAX SA revenue for the last half-year amounts to 6.64 M EUR, despite the estimated figure of 3.44 M EUR. In the next half-year revenue is expected to reach 2.37 M EUR.
2X1 net income for the last half-year is −81.64 M EUR, while the previous report showed −95.79 M EUR of net income which accounts for 14.77% change. Track more ABIVAX SA financial stats to get the full picture.
No, 2X1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 61.00 employees. See our rating of the largest employees — is ABIVAX SA on this list?
Like other stocks, 2X1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIVAX SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABIVAX SA technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABIVAX SA stock shows the strong sell signal. See more of ABIVAX SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.